Continue to site >
Trending ETFs

Name

As of 12/23/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$20.27

$928 M

0.00%

1.66%

Vitals

YTD Return

-4.4%

1 yr return

-4.0%

3 Yr Avg Return

-6.6%

5 Yr Avg Return

-0.7%

Net Assets

$928 M

Holdings in Top 10

46.2%

52 WEEK LOW AND HIGH

$20.1
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 1.66%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 57.85%

Redemption Fee N/A


Min Investment

Standard (Taxable)

N/A

IRA

N/A


Fund Classification

Fund Type

Closed-end mutual fund


Name

As of 12/23/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$20.27

$928 M

0.00%

1.66%

XTHQX - Profile

Distributions

  • YTD Total Return -4.4%
  • 3 Yr Annualized Total Return -6.6%
  • 5 Yr Annualized Total Return -0.7%
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio 0.69%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Monthly

Fund Details

  • Legal Name
    Tekla Healthcare Opportunities Fund
  • Fund Family Name
    Tekla Capital Management LLC
  • Inception Date
    Aug 06, 2014
  • Shares Outstanding
    41356058
  • Share Class
    Other
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Daniel Omstead

Fund Description


XTHQX - Performance

Return Ranking - Trailing

Period XTHQX Return Category Return Low Category Return High Rank in Category (%)
YTD -4.4% -26.9% 19.0% 92.45%
1 Yr -4.0% -26.9% 19.1% 93.08%
3 Yr -6.6%* -27.9% 7.4% 84.21%
5 Yr -0.7%* -11.3% 11.4% 89.93%
10 Yr 3.0%* -0.6% 12.6% 90.27%

* Annualized

Return Ranking - Calendar

Period XTHQX Return Category Return Low Category Return High Rank in Category (%)
2023 -4.5% -12.6% 19.0% 90.57%
2022 -11.8% -53.9% 3.2% 35.53%
2021 15.8% -39.6% 24.2% 5.92%
2020 3.9% -13.6% 178.2% 86.58%
2019 13.8% 3.8% 63.8% 87.97%

Total Return Ranking - Trailing

Period XTHQX Return Category Return Low Category Return High Rank in Category (%)
YTD -4.4% -26.9% 19.0% 92.45%
1 Yr -4.0% -26.9% 19.1% 93.08%
3 Yr -6.6%* -27.9% 7.4% 84.21%
5 Yr -0.7%* -11.3% 11.4% 89.93%
10 Yr 3.0%* -0.6% 12.6% 90.27%

* Annualized

Total Return Ranking - Calendar

Period XTHQX Return Category Return Low Category Return High Rank in Category (%)
2023 -4.5% -12.6% 19.0% 93.08%
2022 -11.8% -53.9% 3.7% 57.24%
2021 15.8% -33.9% 26.0% 21.05%
2020 3.9% -0.7% 180.6% 97.99%
2019 17.9% 4.6% 63.8% 95.49%

NAV & Total Return History


XTHQX - Holdings

Concentration Analysis

XTHQX Category Low Category High XTHQX % Rank
Net Assets 928 M 6.43 M 45.7 B 48.43%
Number of Holdings 185 25 430 6.92%
Net Assets in Top 10 456 M 2.55 M 23.9 B 49.69%
Weighting of Top 10 46.18% 18.9% 78.1% 53.46%

Top 10 Holdings

  1. UnitedHealth Group Inc 10.51%
  2. Johnson & Johnson 6.49%
  3. AbbVie Inc 5.16%
  4. Abbott Laboratories 4.11%
  5. Danaher Corp 3.80%
  6. Anthem Inc 3.75%
  7. Pfizer Inc 3.64%
  8. Thermo Fisher Scientific Inc 3.56%
  9. Eli Lilly and Co 3.52%
  10. Bristol-Myers Squibb Company 3.43%

Asset Allocation

Weighting Return Low Return High XTHQX % Rank
Stocks
106.13% 89.92% 106.13% 0.63%
Bonds
12.39% 0.00% 12.39% 0.63%
Cash
3.26% 0.00% 33.01% 37.74%
Preferred Stocks
1.21% 0.00% 7.86% 20.13%
Convertible Bonds
0.00% 0.00% 0.37% 91.56%
Other
-22.99% -22.99% 23.24% 100.00%

Stock Sector Breakdown

Weighting Return Low Return High XTHQX % Rank
Healthcare
94.11% 59.26% 100.00% 98.05%
Real Estate
5.89% 0.00% 5.89% 0.65%
Utilities
0.00% 0.00% 0.00% 91.56%
Technology
0.00% 0.00% 22.69% 92.21%
Industrials
0.00% 0.00% 7.02% 92.21%
Financial Services
0.00% 0.00% 1.60% 94.81%
Energy
0.00% 0.00% 0.00% 91.56%
Communication Services
0.00% 0.00% 9.11% 91.56%
Consumer Defense
0.00% 0.00% 25.73% 94.16%
Consumer Cyclical
0.00% 0.00% 1.92% 92.86%
Basic Materials
0.00% 0.00% 7.16% 92.86%

Stock Geographic Breakdown

Weighting Return Low Return High XTHQX % Rank
US
104.41% 61.27% 104.41% 0.63%
Non US
1.72% 0.00% 34.10% 52.83%

Bond Sector Breakdown

Weighting Return Low Return High XTHQX % Rank
Corporate
80.68% 0.00% 81.57% 1.45%
Cash & Equivalents
19.32% 0.00% 100.00% 5.66%
Derivative
0.00% -0.01% 23.24% 91.82%
Securitized
0.00% 0.00% 0.00% 91.30%
Municipal
0.00% 0.00% 0.00% 91.30%
Government
0.00% 0.00% 29.44% 92.03%

Bond Geographic Breakdown

Weighting Return Low Return High XTHQX % Rank
US
11.75% 0.00% 11.75% 0.63%
Non US
0.64% 0.00% 3.33% 1.26%

XTHQX - Expenses

Operational Fees

XTHQX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.66% 0.08% 4.48% 28.93%
Management Fee 1.00% 0.03% 1.25% 93.08%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

XTHQX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 1.00% N/A

Trading Fees

XTHQX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

XTHQX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 57.85% 0.00% 238.00% 62.96%

XTHQX - Distributions

Dividend Yield Analysis

XTHQX Category Low Category High XTHQX % Rank
Dividend Yield 0.00% 0.00% 6.24% 95.60%

Dividend Distribution Analysis

XTHQX Category Low Category High Category Mod
Dividend Distribution Frequency Monthly Annual Annual Annual

Net Income Ratio Analysis

XTHQX Category Low Category High XTHQX % Rank
Net Income Ratio 0.69% -2.54% 1.85% 11.18%

Capital Gain Distribution Analysis

XTHQX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually

Distributions History

View More +

XTHQX - Fund Manager Analysis

Managers

Daniel Omstead


Start Date

Tenure

Tenure Rank

Jul 28, 2014

7.85

7.9%

Omstead is president and chief executive officer of Tekla Capital Management, formerly known as Hambrecht & Quist Capital Management, Inc. Before joining the adviser, Omstead was president and CEO of Reprogenesis, Inc., a private development stage biotech company developing therapies in the field of regenerative medicine. Before joining Reprogenesis, he was senior vice president, research and development at Cytotherapeutics, Inc., a public biotech company that developed CNS therapies.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.88 0.25